ParkerVision (PRKR) 10-K 21 Mar 24 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 15, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0000914139
Entity Registrant Name	PARKERVISION INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	000-22904
Entity Incorporation, State or Country Code	FL
Entity Tax Identification Number	59-2971472
Entity Address, Address Line One	4446-1A Hendricks Avenue, Suite 354
Entity Address, City or Town	Jacksonville
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32207
City Area Code	904
Local Phone Number	732-6100
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 7,864,384
Entity Common Stock, Shares Outstanding		88,295,803
Auditor Firm ID	569
Auditor Name	MSL, P.A.
Auditor Location	Fort Lauderdale, Florida

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 2,560	$ 109
Prepaid expenses	61	244
Other current assets	34	30
Total current assets	2,655	383
Intangible assets, net	1,055	1,359
Other assets, net	313	9
Total assets	4,023	1,751
CURRENT LIABILITIES:
Accounts payable	573	901
Accrued expenses:
Salaries and wages	23	23
Professional fees	67	79
Other accrued expenses	447	490
Convertible notes, current portion	1,045	625
Related party note payable, current portion	134	139
Total current liabilities	2,289	2,257
LONG-TERM LIABILITIES:
Secured contingent payment obligation	29,402	40,708
Unsecured contingent payment obligations	7,618	5,089
Convertible notes, net of current portion	3,893	3,913
Related party note payable, net of current portion	340	473
Total long-term liabilities	41,253	50,183
Total liabilities	43,542	52,440
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' DEFICIT:
Common stock, $.01 par value, 175,000 shares authorized, 87,681 and 81,246 issued and outstanding at December 31, 2023 and 2022, respectively	877	812
Additional paid-in capital	393,314	391,724
Accumulated deficit	(433,710)	(443,225)
Total shareholders' deficit	(39,519)	(50,689)
Total liabilities and shareholders' deficit	$ 4,023	$ 1,751

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares shares in Thousands	Dec. 31, 2023	Dec. 31, 2022
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	175,000	175,000
Common stock, shares issued (in shares)	87,681	81,246
Common stock, shares outstanding (in shares)	87,681	81,246

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Licensing revenue	$ 25,000	$ 925
Cost of sales	(227)	(10)
Gross margin	24,773	915
Selling, general, and administrative expenses	14,744	7,773
Total operating expenses	14,744	7,773
Interest and other income	58	103
Interest and other expense	(424)	(324)
Change in fair value of contingent payment obligations	(148)	(2,734)
Total interest and other	(514)	(2,955)
Net income (loss) before income tax	9,515	(9,813)
Provision for income taxes	0	0
Net income (loss)	9,515	(9,813)
Other comprehensive income, net of tax	0	0
Comprehensive income (loss)	$ 9,515	$ (9,813)
Earnings (loss) per common share
Basic (in dollars per share)	$ 0.11	$ (0.13)
Diluted (in dollars per share)	$ 0.08	$ (0.13)
Weighted average common shares outstanding
Basic (in shares)	85,732	78,395
Diluted (in shares)	119,888	78,395

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Deficit - USD ($) $ in Thousands	Conversion and Payment of Interest-in-kind on Convertible Debt [Member] Common Stock [Member]	Conversion and Payment of Interest-in-kind on Convertible Debt [Member] Additional Paid-in Capital [Member]	Conversion and Payment of Interest-in-kind on Convertible Debt [Member] Retained Earnings [Member]	Conversion and Payment of Interest-in-kind on Convertible Debt [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021					$ 770	$ 387,865	$ (433,412)	$ (44,777)
Issuance of common stock and warrants in public and private offerings, net of issuance costs					20	362	0	382
Issuance of common stock upon exercise of options and warrants					5	78	0	83
Issuance of common stock and warrants for services					2	57	0	59
Issuance of common stock upon conversion and payment of interest in kind on convertible debt	$ 14	$ 282	$ 0	$ 296
Share-based compensation, net of shares withheld for taxes					1	3,080	0	3,081
Net income (loss)					0	0	(9,813)	(9,813)
Balance at Dec. 31, 2022					812	391,724	(443,225)	(50,689)
Issuance of common stock and warrants in public and private offerings, net of issuance costs					8	422	0	430
Issuance of common stock upon exercise of options and warrants					1	3	0	4
Issuance of common stock upon conversion and payment of interest in kind on convertible debt	$ 49	$ 542	$ 0	$ 591
Share-based compensation, net of shares withheld for taxes					2	501	0	503
Net income (loss)					0	0	9,515	9,515
Issuance of common stock, warrants, and options for services					5	122	0	127
Balance at Dec. 31, 2023					$ 877	$ 393,314	$ (433,710)	$ (39,519)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 9,515	$ (9,813)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	256	311
Share-based compensation	503	3,081
Change in fair value of contingent payment obligations	148	2,734
Loss on disposal/impairment of equipment and intangible assets	55	124
Paid in kind interest expense	402	299
Changes in operating assets and liabilities:
Prepaid expenses and other assets	306	396
Accounts payable and accrued expenses	(394)	(91)
Total adjustments	1,276	6,854
Net cash provided by (used in) operating activities	10,791	(2,959)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(2)	(4)
Net cash used in investing activities	(2)	(4)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock in private offerings	121	382
Net proceeds from exercise of options and warrants	4	83
Net cash (used in) provided by financing activities	(8,338)	2,042
NET CHANGE IN CASH AND CASH EQUIVALENTS	2,451	(921)
CASH AND CASH EQUIVALENTS, beginning of year	109	1,030
CASH AND CASH EQUIVALENTS, end of year	2,560	109
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	24	24
Cash paid for income taxes	0	0
Contingent Payment Obligation [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Issuance of Long-Term Debt	5,000	0
Repayments of Long-Term Debt	(13,925)	0
Notes Payable, Other Payables [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Issuance of Long-Term Debt	800	1,668
Repayments of Long-Term Debt	$ (338)	$ (91)

Note 1 - Significant Accounting

Note 1 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. SIGNIFICANT ACCOUNTING POLICIES ParkerVision, Inc. and its wholly-owned German subsidiary, ParkerVision GmbH (collectively “ParkerVision”, “we” or the “Company”) is in the business of innovating fundamental wireless hardware technologies and products. We have determined that our business currently operates under a single operating and reportable segment. We have designed and developed proprietary radio frequency (“RF”) technologies and integrated circuits based on those technologies, and we license our technologies to others for use in wireless communication products. We have expended significant financial and other resources to research and develop our RF technologies and to obtain patent protection for those technologies in the United States of America (“U.S.”) and certain foreign jurisdictions. We believe certain patents protecting our proprietary technologies have been broadly infringed by others, and therefore the primary focus of our business plan is the enforcement of our intellectual property rights through patent licensing and infringement litigation efforts. We currently have patent enforcement actions ongoing in various U.S. district courts against mobile handset, smart television and other WiFi product providers, as well as semiconductor suppliers, for the infringement of a number of our RF patents. We have made significant investments in developing and protecting our technologies, the returns on which are dependent upon the generation of future revenues for realization. Basis of Presentation Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”). Certain reclassifications have been made to prior period amounts to conform to the current period presentation. The consolidated financial statements include the accounts of ParkerVision, Inc. and our wholly-owned German subsidiary, ParkerVision GmbH, after elimination of all intercompany transactions and accounts. As of December 31, 2023, no Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The more significant estimates made by us include projected future cash flows and risk-adjusted discount rates for estimating the fair value of our contingent payment obligations, the volatility and estimated lives of share-based awards used in the estimate of the fair market value of share-based compensation, the assessment of recoverability of long-lived assets, the amortization periods for intangible and long-lived assets, and the valuation allowance for deferred taxes. Actual results could differ from the estimates made. We periodically evaluate estimates used in the preparation of the financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Cash and Cash Equivalents We consider cash and cash equivalents to include cash on hand, interest-bearing deposits, overnight repurchase agreements and investments with original maturities of three Intangible Assets We capitalize outside legal costs and agency filing fees incurred in connection with securing the rights to our intellectual property. Patents, copyrights, and other intangible assets are amortized using the straight-line method over their estimated period of benefit. We estimate the economic lives of our patents and copyrights to be fifteen twenty may may Contingent Payment Obligations We have accounted for our secured and unsecured contingent payment obligations as long-term debt in accordance with Accounting Standards Codification (“ASC”) 470 10 25, 825, 3 11 Leases We account for finance and operating leases in accordance with ASC 842, 12 No December 31, 2023 2022 December 31, 2023 2022 not Revenue Recognition We account for revenue under ASC 606, five 1 2 3 4 5 Our revenue is derived from patent licensing and settlement agreements. We have an active monitoring and enforcement program with respect to our intellectual property rights that includes seeking appropriate compensation from third may may Refer to Note 3 Cost of Sales Cost of sales includes amortization of intangible assets directly linked with revenue generating licensing activities. Amortization expense for intangible assets that are not February 2023, Accounting for Share-Based Compensation We have various share-based compensation programs which provide for equity awards including stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”). We calculate the fair value of share-based equity awards on the date of grant and recognize the calculated fair value as compensation expense over the requisite service periods of the related awards. We estimate the fair value of stock option awards using the Black-Scholes option valuation model. This valuation model requires the use of highly subjective assumptions and estimates including how long employees will retain their stock options before exercising them and the volatility of our common stock price over the expected life of the equity award. Such estimates, and the basis for our conclusions regarding such estimates, are outlined in detail in Note 15. not Income Taxes The provision for income taxes is based on income (loss) before taxes as reported in the accompanying consolidated statements of comprehensive income (loss). Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when, based on available objective evidence, it is more likely than not not not not

Note 2 - Liquidity and Going Co

Note 2 - Liquidity and Going Concern	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. LIQUIDITY AND GOING CONCERN The accompanying consolidated financial statements as of and for the year ended December 31, 2023 one not With the exception of the year ended December 31, 2023 third December 31, 2023 For the year ended December 31, 2023 December 31, 2023 Despite the net income and cash flows generated during the year ended December 31, 2023 may first not June 2024 January 2025. one Our business plan is currently focused solely on our patent enforcement and technology licensing objectives. The timing and amount of proceeds from our patent enforcement actions are difficult to predict and there can be no 13 Significant portions of our litigation costs to date have been funded by contingent payment arrangements with legal counsel. Fee discounts offered by legal counsel in exchange for contingent payments upon successful outcome in our litigation are not Our current capital resources are not twelve may twelve twelve may not We expect to continue to invest in the support of our patent licensing and enforcement program. The long-term continuation of our business plan is dependent upon the generation of sufficient cash flows from our technologies and or products to offset expenses and debt obligations. In the event that we do not

Note 3 - Revenue

Note 3 - Revenue	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3. REVENUE During the years ended December 31, 2023 2022 no no no no December 31, 2023

Note 4 - Earnings Per Share

Note 4 - Earnings Per Share	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	4. EARNINGS PER SHARE Basic earnings per common share is determined based on the weighted-average number of common shares outstanding during each period. Diluted loss per common share is the same as basic loss per common share for the year ended December 31, 2022, December 31, 2023 2022 Year Ended December 31, 2023 2022 Numerator: Net income (loss) $ 9,515 $ (9,813 ) Effect of dilutive securities 402 - Net income (loss) adjusted for dilutive effect 9,917 (9,813 ) Denominator: Weighted-average basic shares outstanding 85,732 78,395 Effect of dilutive securities 34,156 - Weighted-average diluted shares 119,888 78,395 Basic earnings (loss) per share $ 0.11 $ (0.13 ) Diluted earnings (loss) per share $ 0.08 $ (0.13 ) Diluted earnings per common share for the years ended December 31, 2023 2022 December 31, 2023 2022 2023 2022 Options outstanding 26,034 24,380 Warrants outstanding 10,346 10,346 Shares underlying convertible notes - 32,734 36,380 67,460

Note 5 - Prepaid Expenses

Note 5 - Prepaid Expenses	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Prepaid Expenses [Text Block]	5. PREPAID EXPENSES Prepaid expenses consisted of the following at December 31, 2023 2022 2023 2022 Prepaid services $ 31 $ 202 Prepaid insurance 12 25 Prepaid licenses, software tools and support 16 15 Other prepaid expenses 2 2 $ 61 $ 244 Prepaid services at December 31, 2022 December 31, 2023.

Note 6 - Intangible Assets

Note 6 - Intangible Assets	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	6. INTANGIBLE ASSETS Intangible assets consisted of the following at December 31, 2023 2022 2023 2022 Patents and copyrights $ 10,431 $ 14,319 Less accumulated amortization (9,376 ) (12,960 ) $ 1,055 $ 1,359 Amortization expense for the years ended December 31, 2023 2022 December 31, 2023 2022 Future estimated amortization expense for intangible assets that have remaining unamortized amounts as of December 31, 2023 2024 $ 228 2025 193 2026 132 2027 115 2028 99 2029 and thereafter 288 Total $ 1,055

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7. ACCRUED LIABILITIES Other accrued expenses consisted of the following at December 31, 2023 2022 2023 2022 Advances $ 375 $ 425 Accrued interest 66 56 Other accrued expenses 6 9 $ 447 $ 490 Advances include amounts received from litigation counsel as advanced reimbursement of out-of-pocket expenses expected to be incurred by us.

Note 8 - Notes Payable

Note 8 - Notes Payable	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Long-Term Debt [Text Block]	8. NOTES PAYABLE Note Payable to a Related Party We have an unsecured promissory note payable of $0.5 million to Sterne, Kessler, Goldstein, & Fox, PLLC (“SKGF”), a related party (see Note 16 April 30, 2027. December 31, 2023 2022 At December 31, 2023 2024 $ 134 2025 139 2026 144 2027 57 Total $ 474 The estimated fair value of our notes payable at December 31, 2023

Note 9 - Convertible Notes

Note 9 - Convertible Notes	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Convertible Debt [Text Block]	9. CONVERTIBLE NOTES Our convertible notes represent promissory notes that are convertible, at the holders’ option, into shares of our common stock at fixed conversion prices. Interest payments are made on a quarterly basis and are payable, at our option and subject to certain equity conditions, in either cash, shares of our common stock, or a combination thereof. The number of shares issued for interest is determined by dividing the interest payment amount by the closing price of our common stock on the trading day immediately prior to the scheduled interest payment date. To date, all interest payments on the convertible notes have been made in shares of our common stock. We have recognized the convertible notes as debt in our consolidated financial statements. We have the option to prepay the majority of the notes any time following the one two three four may In September 2023, 16 January 2023, five "January 2023 January 2023 May 11, 2023 ( No. 333 271351 2022 five August 22, 2022 ( No. 333 266777 For the year ended December 31, 2023 December 31, 2023 2022 September 15, 2023, September 18, 2018, September 18, 2023. March 18, 2026. September 15, 2023, February 28, 2019 March 13, 2019 February 28, 2024 March 13, 2024 February 28, 2026 March 13, 2026, 470 60. No At the holders’ option, subject to ownership limitations, the convertible notes outstanding at December 31, 2023 36.4 With the exception of the shares underlying the September 15, 2023 For the years ended December 31, 2023 2022 December 31, 2023 2022 Convertible notes payable at December 31, 2023 2022 Fixed Conversion Interest December 31, Description Rate Rate Maturity Date 2023 2022 Convertible notes dated September 10, 2018 $ 0.40 8.0 % September 7, 2023 $ - $ 200 Convertible notes dated September 18, 2018 $ 0.25 1 8.0 % March 18, 2026 1 425 425 Convertible notes dated February/March 2019 $ 0.25 8.0 % February 28, 2026 to March 13, 2026 2 750 750 Convertible notes dated June/July 2019 $ 0.10 8.0 % June 7, 2024 to July 15, 2024 295 295 Convertible notes dated July 18, 2019 $ 0.08 7.5 % July 18, 2024 700 700 Convertible notes dated September 13, 2019 $ 0.10 8.0 % September 13, 2024 50 50 Convertible notes dated January 8, 2020 $ 0.13 8.0 % January 8, 2025 3 450 450 Convertible notes dated May-August 2022 $ 0.13 8.0 % May 10, 2027 to August 3, 2027 1,468 1,668 Convertible note dated January 11, 2023 $ 0.16 9.0 % January 11, 2028 3 500 - Convertible notes dated January 13, 2023 $ 0.16 9.0 % January 13, 2028 200 - Convertible note dated September 15, 2023 $ 0.25 8.0 % March 15, 2026 100 - Total principal balance 4,938 4,538 Less current portion 1,045 625 $ 3,893 $ 3,913 1 These notes were amended on September 15, 2023, September 18, 2023 March 18, 2026. 470 60. 2 These notes were amended on September 15, 2023, February 28, 2024 March 13, 2024 February 28, 2026 March 13, 2026. 470 60. 3 may one ten At December 31, 2023 2

Note 10 - Contingent Payment Ob

Note 10 - Contingent Payment Obligations	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Contingencies Disclosure [Text Block]	10. CONTINGENT PAYMENT OBLIGATIONS Secured Contingent Payment Obligation The following table provides a reconciliation of our secured contingent payment obligation measured at estimated fair market value for the years ended December 31, 2023 2022 2023 2022 Secured contingent payment obligation, beginning of year $ 40,708 $ 37,372 Proceeds from contingent payment obligation 5,000 - Repayment (13,925 ) - Change in fair value (2,381 ) 3,336 Secured contingent payment obligation, end of year $ 29,402 $ 40,708 Our secured contingent payment obligation represents the estimated fair value of our repayment obligation to Brickell Key Investments, LP (“Brickell”) under a February 2016 August 14, 2023, August 14, 2028. one hundred first zero not not To date, we have received aggregate proceeds of $23 million in exchange for Brickell’s right to reimbursement and compensation from gross proceeds resulting from patent enforcement and other patent monetization actions and have repaid an aggregate of $17.3 million from patent license and settlement proceeds. The underlying carrying value of the Note, which includes the Face Value plus accrued interest, was approximately $51.0 million as of December 31, 2023, December 31, 2022. 11. Brickell holds a senior security interest in the majority of our assets until such time as the Note, including accrued interest thereon, is paid in full. The security interest is enforceable by Brickell in the event that we are in default under the agreement which would occur if (i) we fail, after notice, to pay proceeds to Brickell, (ii) we become insolvent or insolvency proceedings are commenced (and not not December 31, 2023 We have elected to measure our secured contingent payment obligation at its estimated fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods (see Note 11 Unsecured Contingent Payment Obligations The following table provides a reconciliation of our unsecured contingent payment obligations, measured at estimated fair market value, for the years ended December 31, 2023 2022 2023 2022 Unsecured contingent payment obligations, beginning of year $ 5,089 $ 5,691 Change in fair value 2,529 (602 ) Unsecured contingent payment obligations, end of year $ 7,618 $ 5,089  Our unsecured contingent payment obligations represent amounts payable to others from future patent-related proceeds including (i) a termination fee due to a litigation funder (“Termination Fee”) and (ii) contingent payment rights (“CPRs”) issued to accredited investors primarily in connection with equity financings. We have elected to measure these unsecured contingent payment obligations at their estimated fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods. The unsecured contingent payment obligations will be remeasured to fair value at each reporting period with changes recorded in the consolidated statements of comprehensive income (loss) until the contingency is resolved (see Note 11  The Termination Fee is a result of $1.0 million in advances received under a letter agreement with a third not March 31, 2020, five not March 31, 2020, December 31, 2023 The CPRs represent the estimated fair value of rights provided to accredited investors who purchased shares of our common stock in 2020 2021 third December 31, 2020. December 31, 2023 2022 December 31, 2023

Note 11 - Fair Value Measuremen

Note 11 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	11. FAIR VALUE MEASUREMENTS ASC 820, three ● Level 1: ● Level 2: 1 ● Level 3: The following table summarizes financial assets and financial liabilities carried at fair value and measured on a recurring basis as of December 31, 2023 2022 Fair Value Measurements Total Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2023: Liabilities: Secured contingent payment obligation $ 29,402 $ - $ - $ 29,402 Unsecured contingent payment obligations 7,618 - - 7,618 December 31, 2022: Liabilities: Secured contingent payment obligation 40,708 - - 40,708 Unsecured contingent payment obligations 5,089 - - 5,089 For the years ended December 31, 2023 2022 no The fair values of our secured and unsecured contingent payment obligations were estimated using a probability-weighted income approach based on various cash flow scenarios as to the outcome of patent-related actions both in terms of timing and amount, discounted to present value using a risk-adjusted rate. We used a risk-adjusted discount rate for the secured and unsecured contingent payment obligations of 18.12% and 18.51%, respectively, at December 31, 2023 The following table provides quantitative information about the significant unobservable inputs used in the measurement of fair value for both the secured and unsecured contingent payment obligations at December 31, 2023 Secured Contingent Payment Obligation Unsecured Contingent Payment Obligations Unobservable Inputs Low Weighted Average High Low Weighted Average High Estimated undiscounted cash outflows (in millions) $ 0.0 $ 43.1 $ 79.6 $ 0.0 $ 9.7 $ 10.8 Duration (in years) 0.5 2.3 3.5 0.5 1.4 3.5 Estimated probabilities 5 % 20 % 35 % 5 % 23 % 35 % We evaluate the estimates and assumptions used in determining the fair value of our contingent payment obligations each reporting period and make any adjustments prospectively based on those evaluations. Changes in any of these Level 3

Note 12 - Income Taxes and Tax

Note 12 - Income Taxes and Tax Status	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. INCOME TAXES AND TAX STATUS Our net income (loss) before income tax for the years ended December 31, 2023 2022 No current or deferred tax provision was recorded in 2023 not 2022 A reconciliation between the provision for income taxes and the expected tax benefit using the federal statutory rate of 21% for each of the years ended December 31, 2023 2022 2023 2022 Tax expense (benefit) at statutory rate $ 1,998 $ (2,061 ) State tax expense (benefit) 409 (422 ) (Decrease) increase in valuation allowance (2,512 ) 2,416 Other 105 67 $ - $ - Our deferred tax assets and liabilities relate to the following sources and differences between financial accounting and the tax bases of our assets and liabilities at December 31, 2023 2022 2023 2022 Gross deferred tax assets: Net operating loss carry-forward $ 70,159 $ 75,470 Research and development credit carry-forward 4,565 5,356 Stock compensation 1,350 1,127 Patents and other 568 1,482 Contingent payment obligations 7,071 7,033 Fixed assets (1 ) (2 ) Charitable contributions 2 - Lease liabilities - 1 83,714 90,467 Less valuation allowance (83,714 ) (90,467 ) Net deferred tax asset $ - $ - At December 31, 2023 2024 2037. December 31, 2023 2024 2038. Our ability to benefit from the NOL and tax credit carry-forwards could be limited under certain provisions of the Internal Revenue Code if there are ownership changes of more than 50%, 382 1986 382” 382, may 382, 50 three not December 31, 2023 382. Uncertain Tax Positions We file income tax returns in the U.S. federal jurisdiction, various state jurisdictions, and Germany. We have identified our Federal and Florida tax returns as our only major jurisdictions, as defined. The periods subject to examination for those returns are the 2004 2023 December 31, 2023 2022 2023 2022 Unrecognized tax benefits – beginning of year $ 638 $ 653 Reduction as a result of lapse of statute of limitations - (15 ) Unrecognized tax benefits – end of year $ 638 $ 638 Future changes in the unrecognized tax benefit will have no Our policy is that we recognize interest and penalties accrued on any unrecognized tax benefits as a component of our income tax expense. We do not December 31, 2023 2022 not

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	13. COMMITMENTS AND CONTINGENCIES Legal Proceedings From time to time, we are subject to legal proceedings and claims which arise in the ordinary course of our business. These proceedings include patent enforcement actions initiated by us against others for the infringement of our technologies, as well as proceedings brought by others against us at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (“PTAB”) in an attempt to invalidate certain of our patent claims. The majority of our litigation, including our PTAB proceedings, is being paid for through contingency fee arrangements with our litigation counsel as well as third third ParkerVision v. Qualcomm (Middle District of Florida-Orlando Division) - Appealed to U.S. Court of Appeals for the Federal Circuit In March 2022, not three April 2022, November 6, 2023, This patent infringement case was originally filed in the Middle District of Florida in May 2014. February 2016 6,091,940 ‘940 March 2017, sixth September 2018, ‘940 January 2019, July 2019, ‘940 may September 2019, ‘940 January 2020. In April 2020, 19, December 2020 May 2021. October 2020, December 2020; one January 2021. May 3, 2021 July 6, 2021. In March 2021, not November December 2021. Daubert May 2021. March 2021, 2020 July 2021, No. 7,865,177 ‘177 In January 2022, three March 2022, 30 ParkerVision v. Apple and Qualcomm (Middle District of Florida-Jacksonville Division) In December 2015, February 2016, July 2016, March 2017, May 2017. July 2017, July 2017, March 2018, March 2018 9,118,528 August 31, 2018. July 2019, August 2020. March 2020, 19, April 2020, ParkerVision v. LG (District of New Jersey) In July 2017, ParkerVision v. Apple and Qualcomm March 2018, ParkerVision v. Apple and Qualcomm ParkerVision v. Intel (Western District of Texas) We filed two 2020, first February 6, 2023. November 2022, January 2023. February 6, 2023 February 7, 2023, ParkerVision v. TCL (Western District of Texas) We filed two 2020 2021 first January 2023, ParkerVision v. LGE (Western District of Texas) We filed a patent infringement action in the Western District of Texas against LG Electronics, a South Korean company ("LGE") in 2021, June 2022, January 2023, ParkerVision v. Realtek (Western District of Texas) We filed two first 2022 second 2023, January 2024 first first January 2025. ParkerVision v. MediaTek (Western District of Texas) We filed three first 2022 two 2023, January 2024 first first December 2024. second May 2024 October 2025. ParkerVision v. Texas Instruments (Western District of Texas) We filed a patent infringement action in the Western District of Texas against Texas Instruments ("TI") in 2023, December 2023, not May 2024 May 2025. ParkerVision v. NXP Semiconductors (Western District of Texas) We filed a patent infringement action in the Western District of Texas against NXP Semiconductors ("NXP") in 2023, May 2024 August 2025. Additional Patent Infringement Cases Western District of Texas ParkerVision filed a number of patent cases in the Western District of Texas in 2020 ten 2021 November 2022, two Intel (USPTO) v. ParkerVision (PTAB) Intel filed IPR petitions against U.S. patent 7,539,474 ‘474 7,110,444 ‘444 8,190,108 ‘108 ParkerVision v. Intel January 2022, '474 seven January 2022, '444 '444 July 2022, '444 December 2023, June 2022, '108 '108 April 2024. February 2023  TCL and LGE. v. ParkerVision (PTAB) TCL, along with Hisense, filed IPR petitions against U.S. patent 7,292,835 ‘835 ‘444 December 2021, two April 2022. September 2022. November 2022, November 2022, April 2024. MediaTek v. ParkerVision (PTAB) MediaTek filed an IPR petition in November 2023 ‘835 first

Note 14 - Stock Authorization a

Note 14 - Stock Authorization and Issuance	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Equity [Text Block]	14. STOCK AUTHORIZATION AND ISSUANCE Preferred Stock We have 15 million shares of preferred stock authorized for issuance at the direction of our board of directors (the “Board”). On November 17, 2005, November 2023. December 31, 2023 Common Stock We have 175 million shares of common stock authorized for issuance as of December 31, 2023 September 2022 As of December 31, 2023  Stock and Warrant Issuances Equity Based Financings The following table presents a summary of completed equity-based financing transactions for the years ended December 31, 2023 2022 Date Transaction # of Common Shares/ Units Sold Average Price per Share/ Unit Net Proceeds (1) November 2022 Private placement of common stock 1,000 $ 0.20 $ 200 December 2022 Private placement of common stock 1,000 $ 0.20 $ 200 January 2023 Private placement of common stock 844 $ 0.16 $ 120 ( 1 After deduction of applicable offering costs. Private Placements In January 2023, May 11, 2023 ( No. 333 271651 November December 2022, May 11, 2023 ( No. 333 271351 Stock, Option and Warrant Issuances Payment for Services In April 2023, second 2023, 16 In January 2023, first 2023. August 2022 six On November 22, 2022, third twelve four three November 22, 2022 three May 11, 2023 ( No. 333 271651 In October 2022, December 2024. 2020 March 2023 March 2026. June 2023, In addition, from time to time, we issue share-based compensation awards under our equity compensation plans to third December 31, 2023, 2019 two 15 Common Stock Warrants On December 18, 2023, 2018 18 December 20, 2023, June 20, 2025. five 5 two not five 5 December 31, 2023. We had outstanding warrants for the purchase of up to 10.3 million shares of our common stock as of December 31, 2023 2022 December 31, 2023 2022, December 31, 2023

Note 15 - Share-based Compensat

Note 15 - Share-based Compensation	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	15. SHARE-BASED COMPENSATION For the years ended December 31, 2023 2022 December 31, 2023 Stock Incentive Plans 2019 We adopted a long-term incentive equity plan in August 2019 January 2021 January 2023, not “2019 2019 2019 may not December 31, 2023 2019 2011 We adopted a shareholder approved long-term incentive equity plan in September 2011 2014, 2016 2017 not “2011 January 2023, 2011 December 31, 2023 2011 2011 2008 We adopted an equity incentive plan in August 2008 ( “2008 not no 2008 January 2023, 2008 Restricted Stock Awards RSAs are issued as executive and employee incentive compensation and as payment for services to others. The value of the award is based on the closing price of our common stock on the date of grant. RSAs are generally immediately vested. From time to time, we issue fully vested share-based compensation awards to third 5 Restricted Stock Units RSUs are issued as incentive compensation to executives, employees, and non-employee directors. Each RSU represents a right to one not one three one RSAs and RSUs The following table presents a summary of RSA and RSU activity under the 2011 2019 December 31, 2023 Non-vested Shares Shares Weighted-Average Grant Date Fair Value Non-vested at beginning of year - Granted 370 0.30 Vested (370 ) 0.30 Forfeited - - Non-vested at end of year - $ - The total fair value of RSAs and RSUs vested under the Stock Plans for the years ended December 31, 2023 2022 Stock Options Stock options are issued as incentive compensation to executives, employees, consultants and non-employee directors. Stock options are granted with exercise prices at or above fair market value of the underlying shares at the date of grant. Fair market value of the underlying shares is determined based on observable market prices at the date of the grant. The fair value of options granted is estimated using the Black-Scholes option pricing model. Generally, fair value is determined as of the grant date. Options for employees, including executives and non-employee directors, are generally granted under the Stock Plans. The following table presents a summary of option activity under the Stock Plans for the year ended December 31, 2023 Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term (in years) Aggregate Intrinsic Value ($) Outstanding at beginning of year 24,180 $ 0.41 Granted 2,000 0.26 Exercised (21 ) 0.17 Forfeited/Expired (325 ) 0.86 Outstanding at end of year 25,834 0.40 2.5 $ - Vested at end of year 24,659 $ 0.40 2.4 $ - The weighted average per share fair value of options granted under the Stock Plans during the years ended December 31, 2023 2022 December 31, 2023 2022 The fair value of option grants under the Stock Plans for the years ended December 31, 2023 2022 Year ended December 31, 2023 2022 Expected option term (in years) 1 5 5 Expected volatility factor 2 150.9 - 155.9% 143.9 - 155.9% Risk-free interest rate 3 3.60 - 4.45% 3.05 - 4.09% Expected annual dividend yield 0% 0% 1 2 3 Options by Price Range The options outstanding at December 31, 2023 Options Outstanding Options Vested Range of Exercise Prices Number Outstanding at December 31, 2023 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life Number Exercisable at December 31, 2023 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life $0.171 - $0.3001 11,458 $ 0.19 3.1 10,283 $ 0.18 3.0 $0.33 - $0.495 550 0.33 3.1 550 0.33 3.1 $0.50 - $0.75 13,553 0.54 2.0 13,553 0.54 2.0 $1.98 - $2.97 273 1.98 0.6 273 1.98 0.6 25,834 $ 0.40 2.5 24,659 $ 0.40 2.4 We issue new shares of our common stock upon exercise of options or vesting of RSUs or RSAs under the Stock Plans. The shares underlying the Stock Plans are registered. Cash received from option exercises for the years ended December 31, 2023 2022

Note 16 - Related Party Transac

Note 16 - Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	16. RELATED PARTY TRANSACTIONS We paid approximately $0.05 million and $0.01 million in 2023 2022 one September 2006, 2023 2022 8 December 31, 2023 In April 2023, second 2023, December 31, 2023, 2019 2022 In May 2022, one September 2023, December 31, 2023 In August 2022, October 2022. January 2023,

Note 17 - Concentrations of Cre

Note 17 - Concentrations of Credit Risk	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	17. CONCENTRATIONS OF CREDIT RISK Financial instruments that potentially subject us to a concentration of credit risk principally consist of cash and cash equivalents. Cash and cash equivalents are primarily held in bank accounts and overnight investments. At times our cash balances on deposit with banks may

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Dec. 31, 2023
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	9B. None
Rule 10b5-1 Arrangement Terminated [Flag]	false
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”). Certain reclassifications have been made to prior period amounts to conform to the current period presentation. The consolidated financial statements include the accounts of ParkerVision, Inc. and our wholly-owned German subsidiary, ParkerVision GmbH, after elimination of all intercompany transactions and accounts. As of December 31, 2023, no
Use of Estimates, Policy [Policy Text Block]	Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The more significant estimates made by us include projected future cash flows and risk-adjusted discount rates for estimating the fair value of our contingent payment obligations, the volatility and estimated lives of share-based awards used in the estimate of the fair market value of share-based compensation, the assessment of recoverability of long-lived assets, the amortization periods for intangible and long-lived assets, and the valuation allowance for deferred taxes. Actual results could differ from the estimates made. We periodically evaluate estimates used in the preparation of the financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents We consider cash and cash equivalents to include cash on hand, interest-bearing deposits, overnight repurchase agreements and investments with original maturities of three
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intangible Assets We capitalize outside legal costs and agency filing fees incurred in connection with securing the rights to our intellectual property. Patents, copyrights, and other intangible assets are amortized using the straight-line method over their estimated period of benefit. We estimate the economic lives of our patents and copyrights to be fifteen twenty may may
Contingent Payment Obligations [Policy Text Block]	Contingent Payment Obligations We have accounted for our secured and unsecured contingent payment obligations as long-term debt in accordance with Accounting Standards Codification (“ASC”) 470 10 25, 825, 3 11
Lessee, Leases [Policy Text Block]	Leases We account for finance and operating leases in accordance with ASC 842, 12 No December 31, 2023 2022 December 31, 2023 2022 not
Revenue [Policy Text Block]	Revenue Recognition We account for revenue under ASC 606, five 1 2 3 4 5 Our revenue is derived from patent licensing and settlement agreements. We have an active monitoring and enforcement program with respect to our intellectual property rights that includes seeking appropriate compensation from third may may Refer to Note 3
Cost of Goods and Service [Policy Text Block]	Cost of Sales Cost of sales includes amortization of intangible assets directly linked with revenue generating licensing activities. Amortization expense for intangible assets that are not February 2023,
Share-Based Payment Arrangement [Policy Text Block]	Accounting for Share-Based Compensation We have various share-based compensation programs which provide for equity awards including stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”). We calculate the fair value of share-based equity awards on the date of grant and recognize the calculated fair value as compensation expense over the requisite service periods of the related awards. We estimate the fair value of stock option awards using the Black-Scholes option valuation model. This valuation model requires the use of highly subjective assumptions and estimates including how long employees will retain their stock options before exercising them and the volatility of our common stock price over the expected life of the equity award. Such estimates, and the basis for our conclusions regarding such estimates, are outlined in detail in Note 15. not
Income Tax, Policy [Policy Text Block]	Income Taxes The provision for income taxes is based on income (loss) before taxes as reported in the accompanying consolidated statements of comprehensive income (loss). Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when, based on available objective evidence, it is more likely than not not not not

Note 4 - Earnings Per Share (Ta

Note 4 - Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 2023 2022 Numerator: Net income (loss) $ 9,515 $ (9,813 ) Effect of dilutive securities 402 - Net income (loss) adjusted for dilutive effect 9,917 (9,813 ) Denominator: Weighted-average basic shares outstanding 85,732 78,395 Effect of dilutive securities 34,156 - Weighted-average diluted shares 119,888 78,395 Basic earnings (loss) per share $ 0.11 $ (0.13 ) Diluted earnings (loss) per share $ 0.08 $ (0.13 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2023 2022 Options outstanding 26,034 24,380 Warrants outstanding 10,346 10,346 Shares underlying convertible notes - 32,734 36,380 67,460

Note 5 - Prepaid Expenses (Tabl

Note 5 - Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	2023 2022 Prepaid services $ 31 $ 202 Prepaid insurance 12 25 Prepaid licenses, software tools and support 16 15 Other prepaid expenses 2 2 $ 61 $ 244

Note 6 - Intangible Assets (Tab

Note 6 - Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	2023 2022 Patents and copyrights $ 10,431 $ 14,319 Less accumulated amortization (9,376 ) (12,960 ) $ 1,055 $ 1,359
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2024 $ 228 2025 193 2026 132 2027 115 2028 99 2029 and thereafter 288 Total $ 1,055

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	2023 2022 Advances $ 375 $ 425 Accrued interest 66 56 Other accrued expenses 6 9 $ 447 $ 490

Note 8 - Notes Payable (Tables)

Note 8 - Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Maturities of Long-Term Debt [Table Text Block]	2024 $ 134 2025 139 2026 144 2027 57 Total $ 474

Note 9 - Convertible Notes (Tab

Note 9 - Convertible Notes (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Convertible Debt [Table Text Block]	Fixed Conversion Interest December 31, Description Rate Rate Maturity Date 2023 2022 Convertible notes dated September 10, 2018 $ 0.40 8.0 % September 7, 2023 $ - $ 200 Convertible notes dated September 18, 2018 $ 0.25 1 8.0 % March 18, 2026 1 425 425 Convertible notes dated February/March 2019 $ 0.25 8.0 % February 28, 2026 to March 13, 2026 2 750 750 Convertible notes dated June/July 2019 $ 0.10 8.0 % June 7, 2024 to July 15, 2024 295 295 Convertible notes dated July 18, 2019 $ 0.08 7.5 % July 18, 2024 700 700 Convertible notes dated September 13, 2019 $ 0.10 8.0 % September 13, 2024 50 50 Convertible notes dated January 8, 2020 $ 0.13 8.0 % January 8, 2025 3 450 450 Convertible notes dated May-August 2022 $ 0.13 8.0 % May 10, 2027 to August 3, 2027 1,468 1,668 Convertible note dated January 11, 2023 $ 0.16 9.0 % January 11, 2028 3 500 - Convertible notes dated January 13, 2023 $ 0.16 9.0 % January 13, 2028 200 - Convertible note dated September 15, 2023 $ 0.25 8.0 % March 15, 2026 100 - Total principal balance 4,938 4,538 Less current portion 1,045 625 $ 3,893 $ 3,913

Note 10 - Contingent Payment _2

Note 10 - Contingent Payment Obligations (Tables)	12 Months Ended
	Dec. 31, 2023
Unsecured Debt [Member]
Notes Tables
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	2023 2022 Unsecured contingent payment obligations, beginning of year $ 5,089 $ 5,691 Change in fair value 2,529 (602 ) Unsecured contingent payment obligations, end of year $ 7,618 $ 5,089
Secured Debt [Member]
Notes Tables
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	2023 2022 Secured contingent payment obligation, beginning of year $ 40,708 $ 37,372 Proceeds from contingent payment obligation 5,000 - Repayment (13,925 ) - Change in fair value (2,381 ) 3,336 Secured contingent payment obligation, end of year $ 29,402 $ 40,708

Note 11 - Fair Value Measurem_2

Note 11 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Fair Value Measurements Total Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2023: Liabilities: Secured contingent payment obligation $ 29,402 $ - $ - $ 29,402 Unsecured contingent payment obligations 7,618 - - 7,618 December 31, 2022: Liabilities: Secured contingent payment obligation 40,708 - - 40,708 Unsecured contingent payment obligations 5,089 - - 5,089
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Secured Contingent Payment Obligation Unsecured Contingent Payment Obligations Unobservable Inputs Low Weighted Average High Low Weighted Average High Estimated undiscounted cash outflows (in millions) $ 0.0 $ 43.1 $ 79.6 $ 0.0 $ 9.7 $ 10.8 Duration (in years) 0.5 2.3 3.5 0.5 1.4 3.5 Estimated probabilities 5 % 20 % 35 % 5 % 23 % 35 %

Note 12 - Income Taxes and Ta_2

Note 12 - Income Taxes and Tax Status (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2023 2022 Tax expense (benefit) at statutory rate $ 1,998 $ (2,061 ) State tax expense (benefit) 409 (422 ) (Decrease) increase in valuation allowance (2,512 ) 2,416 Other 105 67 $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2023 2022 Gross deferred tax assets: Net operating loss carry-forward $ 70,159 $ 75,470 Research and development credit carry-forward 4,565 5,356 Stock compensation 1,350 1,127 Patents and other 568 1,482 Contingent payment obligations 7,071 7,033 Fixed assets (1 ) (2 ) Charitable contributions 2 - Lease liabilities - 1 83,714 90,467 Less valuation allowance (83,714 ) (90,467 ) Net deferred tax asset $ - $ -
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	2023 2022 Unrecognized tax benefits – beginning of year $ 638 $ 653 Reduction as a result of lapse of statute of limitations - (15 ) Unrecognized tax benefits – end of year $ 638 $ 638

Note 14 - Stock Authorization_2

Note 14 - Stock Authorization and Issuance (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Summary of Equity Offerings [Table Text Block]	Date Transaction # of Common Shares/ Units Sold Average Price per Share/ Unit Net Proceeds (1) November 2022 Private placement of common stock 1,000 $ 0.20 $ 200 December 2022 Private placement of common stock 1,000 $ 0.20 $ 200 January 2023 Private placement of common stock 844 $ 0.16 $ 120

Note 15 - Share-based Compens_2

Note 15 - Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Non-vested Shares Shares Weighted-Average Grant Date Fair Value Non-vested at beginning of year - Granted 370 0.30 Vested (370 ) 0.30 Forfeited - - Non-vested at end of year - $ -
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term (in years) Aggregate Intrinsic Value ($) Outstanding at beginning of year 24,180 $ 0.41 Granted 2,000 0.26 Exercised (21 ) 0.17 Forfeited/Expired (325 ) 0.86 Outstanding at end of year 25,834 0.40 2.5 $ - Vested at end of year 24,659 $ 0.40 2.4 $ -
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year ended December 31, 2023 2022 Expected option term (in years) 1 5 5 Expected volatility factor 2 150.9 - 155.9% 143.9 - 155.9% Risk-free interest rate 3 3.60 - 4.45% 3.05 - 4.09% Expected annual dividend yield 0% 0%
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Options Outstanding Options Vested Range of Exercise Prices Number Outstanding at December 31, 2023 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life Number Exercisable at December 31, 2023 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life $0.171 - $0.3001 11,458 $ 0.19 3.1 10,283 $ 0.18 3.0 $0.33 - $0.495 550 0.33 3.1 550 0.33 3.1 $0.50 - $0.75 13,553 0.54 2.0 13,553 0.54 2.0 $1.98 - $2.97 273 1.98 0.6 273 1.98 0.6 25,834 $ 0.40 2.5 24,659 $ 0.40 2.4

Note 1 - Significant Accounti_2

Note 1 - Significant Accounting Policies (Details Textual) - Intellectual Property [Member]	Dec. 31, 2023
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	15 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years

Note 2 - Liquidity and Going _2

Note 2 - Liquidity and Going Concern (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents, at Carrying Value	$ 2,560	$ 109
Net Working Capital	400
Retained Earnings (Accumulated Deficit)	(433,710)	(443,225)
Net Income (Loss) Attributable to Parent	9,515	(9,813)
Net Cash Provided by (Used in) Operating Activities	10,791	(2,959)
Repayments of Related Party Debt	100
Repayments of Convertible Debt	200
Proceeds from Issuance of Debt and Equity	900
Convertible Debt	4,938	4,538
Maturing Between June 2024 and January 2025 [Member]
Convertible Debt	1,500
Contingent Payment Obligation [Member]
Repayments of Long-Term Debt	13,925	0
Proceeds from Issuance of Long-Term Debt	$ 5,000	$ 0

Note 3 - Revenue (Details Textu

Note 3 - Revenue (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Contract with Customer, Liability, Revenue Recognized	$ 25,000	$ 930
Contract with Customer, Liability	0
Contract with Customer, Asset, before Allowance for Credit Loss	$ 0

Note 4 - Earnings Per Share - C

Note 4 - Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Net income (loss)	$ 9,515	$ (9,813)
Effect of dilutive securities	402	0
Net income (loss) adjusted for dilutive effect	$ 9,917	$ (9,813)
Weighted-average basic shares outstanding (in shares)	85,732	78,395
Effect of dilutive securities (in shares)	34,156	0
Weighted-average diluted shares (in shares)	119,888	78,395
Basic earnings (loss) per share (in dollars per share)	$ 0.11	$ (0.13)
Diluted earnings (loss) per share (in dollars per share)	$ 0.08	$ (0.13)

Note 4 - Earnings Per Share - A

Note 4 - Earnings Per Share - Antidilutive Securities (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive securities (in shares)	36,380	67,460
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	26,034	24,380
Warrant [Member]
Antidilutive securities (in shares)	10,346	10,346
Convertible Debt Securities [Member]
Antidilutive securities (in shares)	0	32,734

Note 5 - Prepaid Expenses (Deta

Note 5 - Prepaid Expenses (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Prepaid Services	$ 31	$ 202
Pre Paid Consulting Services [Member]
Prepaid Services	$ 0	$ 200

Note 5 - Prepaid Expenses - Pre

Note 5 - Prepaid Expenses - Prepaid Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Prepaid services	$ 31	$ 202
Prepaid insurance	12	25
Prepaid licenses, software tools and support	16	15
Other prepaid expenses	2	2
Prepaid Expense, Current	$ 61	$ 244

Note 6 - Intangible Assets (Det

Note 6 - Intangible Assets (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Amortization of Intangible Assets	$ 250	$ 300
Gain (Loss) on Disposition of Intangible Assets	$ (60)	$ (120)

Note 6 - Intangible Assets - In

Note 6 - Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Patents and copyrights	$ 10,431	$ 14,319
Less accumulated amortization	(9,376)	(12,960)
Total	$ 1,055	$ 1,359

Note 6 - Intangible Assets - Sc

Note 6 - Intangible Assets - Schedule of Finite Lived Intangible Assets, Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
2024	$ 228
2025	193
2026	132
2027	115
2028	99
2029 and thereafter	288
Total	$ 1,055	$ 1,359

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Advances	$ 375	$ 425
Accrued interest	66	56
Other accrued expenses	6	9
Accrued Liabilities	$ 447	$ 490

Note 8 - Notes Payable (Details

Note 8 - Notes Payable (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Jan. 31, 2023
Convertible Debt [Member]
Debt Instrument, Face Amount			$ 700,000
Debt Instrument, Interest Rate, Stated Percentage	12%
Interest Expense, Debt	$ 400,000	$ 300,000
Notes Payable, Fair Value Disclosure	390,000
Promissory Notes [Member] | Unsecured Debt [Member] | Sterne Kessler Goldstein Fox Pllc [Member]
Debt Instrument, Face Amount	$ 500,000
Debt Instrument, Interest Rate, Stated Percentage	4%
Debt Instrument, Periodic Payment, Total	$ 12,500
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid	20,000
Interest Expense, Debt	$ 20,000	$ 30,000

Note 8 - Notes Payable - Schedu

Note 8 - Notes Payable - Schedule of Maturities of Long-Term Debt (Details) $ in Thousands	Dec. 31, 2023 USD ($)
2024	$ 134
2025	139
2026	144
2027	57
Total	$ 474

Note 9 - Convertible Notes (Det

Note 9 - Convertible Notes (Details Textual) $ / shares in Units, $ in Thousands			1 Months Ended	12 Months Ended
		Sep. 15, 2023 USD ($) $ / shares	Jan. 31, 2023 USD ($) $ / shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares	May 31, 2022 USD ($) $ / shares	Sep. 18, 2018 $ / shares
Convertible Debt				$ 4,938	$ 4,538
Repayments of Convertible Debt				200
Convertible Note Dated September 18, 2018 [Member]
Convertible Debt				$ 425	425
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares	[1]			$ 0.25
Paul Rosenbaum [Member] | Promissory Notes [Member]
Debt Instrument, Term (Year)		2 years 6 months
Convertible Debt		$ 100		$ 200
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares		$ 0.25				$ 0.25	$ 0.13
Debt Instrument, Face Amount						$ 100	$ 100
Debt Instrument, Convertible, Number of Equity Instruments				1,200,000
Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage				12%
Debt Instrument, Term (Year)			5 years
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares		0.25	$ 0.16
Debt Instrument, Face Amount			$ 700
Repayments of Convertible Debt				$ 200
Debt Conversion, Converted Instrument, Amount				$ 200	$ 30
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares				1,500,000	300,000
Interest Expense, Debt				$ 400	$ 300
Notes Payable, Fair Value Disclosure				390
Convertible Debt [Member] | Fair Value, Inputs, Level 2 [Member]
Notes Payable, Fair Value Disclosure				$ 3,700
Convertible Debt [Member] | Conversion and Payment of Interest-in-kind on Convertible Debt [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares				3,336,000	1,203,000
Convertible Debt [Member] | Promissory Notes [Member]
Debt Instrument, Convertible, Number of Equity Instruments				36,400,000
Convertible Debt [Member] | Five-year Convertible Promissory Notes [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares					$ 0.13
Debt Instrument, Face Amount					$ 1,700
Convertible Debt [Member] | Convertible Note Dated September 18, 2018 [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares		$ 0.57
Convertible Debt [Member] | Debt Instrument, Redemption, Period One [Member]
Debt Instrument, Redemption Price, Percentage				25%
Convertible Debt [Member] | Debt Instrument, Redemption, Period Two [Member]
Debt Instrument, Redemption Price, Percentage				20%
Convertible Debt [Member] | Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption Price, Percentage				15%
Convertible Debt [Member] | Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption Price, Percentage				10%
Amended Convertible Notes Dated September 18, 2018 [Member]
Debt Instrument, Term (Year)		2 years 6 months
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares		$ 0.25						$ 0.57
Debt Instrument, Face Amount		$ 430
Amended Convertible Promissory Notes Dated February 28, 2019 and March 13, 2019 [Member]
Debt Instrument, Face Amount		$ 750
Convertible Notes Dated E [Member]
Debt Instrument, Interest Rate, Stated Percentage				2%
[1]These notes were amended on September 15, 2023, reducing the conversion rate from $0.57 per share to $0.25 per share and extending the maturity date from September 18, 2023 to March 18, 2026. The amendments are accounted for on a prospective basis in accordance with ASC 470-60.

Note 9 - Convertible Notes - Sc

Note 9 - Convertible Notes - Schedule Of Convertible Notes Payable (Details) - USD ($) $ / shares in Units, $ in Thousands		Dec. 31, 2023	Dec. 31, 2022
Convertible Debt		$ 4,938	$ 4,538
Less current portion		1,045	625
Convertible Debt, Noncurrent		$ 3,893	3,913
Convertible Notes dated September 10, 2018 [Member]
Fixed Conversion Rate (in dollars per share)		$ 0.4
Effective Interest Rate		8%
Convertible Debt		$ 0	200
Convertible Note Dated September 18, 2018 [Member]
Fixed Conversion Rate (in dollars per share)	[1]	$ 0.25
Effective Interest Rate		8%
Convertible Debt		$ 425	425
Convertible Notes Dated February/March 2019 [Member]
Fixed Conversion Rate (in dollars per share)		$ 0.25
Effective Interest Rate		8%
Convertible Debt		$ 750	750
Convertible Notes Dated June/July 2019 [Member]
Fixed Conversion Rate (in dollars per share)		$ 0.1
Effective Interest Rate		8%
Convertible Debt		$ 295	295
Convertible Notes Dated July 18, 2019 [Member]
Fixed Conversion Rate (in dollars per share)		$ 0.08
Effective Interest Rate		7.50%
Convertible Debt		$ 700	700
Convertible Notes Dated September 13, 2019 [Member]
Fixed Conversion Rate (in dollars per share)		$ 0.1
Effective Interest Rate		8%
Convertible Debt		$ 50	50
Convertible Notes Dated January 8, 2020 [Member]
Fixed Conversion Rate (in dollars per share)		$ 0.13
Effective Interest Rate		8%
Convertible Debt		$ 450	450
Convertible Notes Dated May-August 2022 [Member]
Fixed Conversion Rate (in dollars per share)		$ 0.13
Effective Interest Rate		8%
Convertible Debt		$ 1,468	1,668
Convertible Notes Dated January 11, 2023 [Member]
Fixed Conversion Rate (in dollars per share)		$ 0.16
Effective Interest Rate		9%
Convertible Debt		$ 500	0
Convertible Notes Dated January 13, 2023 [Member]
Fixed Conversion Rate (in dollars per share)		$ 0.16
Effective Interest Rate		9%
Convertible Debt		$ 200	0
Convertible Note Dated September 15, 2023 [Member]
Fixed Conversion Rate (in dollars per share)		$ 0.25
Effective Interest Rate		8%
Convertible Debt		$ 100	$ 0
[1]These notes were amended on September 15, 2023, reducing the conversion rate from $0.57 per share to $0.25 per share and extending the maturity date from September 18, 2023 to March 18, 2026. The amendments are accounted for on a prospective basis in accordance with ASC 470-60.

Note 10 - Contingent Payment _3

Note 10 - Contingent Payment Obligations (Details Textual) - USD ($)	12 Months Ended		24 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2020	Aug. 14, 2023	Mar. 31, 2020
Common Stock With Contingent Payment Rights [Member]
Proceeds from Issuance of Common Stock	$ 0	$ 0
Contingent Payment Rights [Member]
Maximum Amount of Net Proceeds Recoverable	10,000,000
Amount Investors' Subscription is Divided By	10,000,000
Aggregate Proceeds From Contingent Payment Rights	5,800,000
Contingent Payment Obligation [Member]
Contingent Payment Obligation, Minimum Return		$ 56,900,000
Secured, Non-recourse Promissory Note [Member] | Brickell [Member]
Debt Instrument, Face Amount				$ 45,500,000
Debt Instrument, Payment, Percentage of Distributions, First Limit				100%
Debt Instrument, Payment, Distributions, First Limit				$ 5.8
Long-Term Debt, Gross	51,000,000
Secured Debt [Member] | Brickell [Member]
Proceeds from Issuance of Debt	23,000,000
Repayments of Debt	17,300,000
Unsecured Debt [Member] | Termination Fee [Member]
Advances From Funder			$ 1,000,000
Loss Contingency, Estimate of Possible Loss	3,500,000				$ 5,000,000
Unsecured Debt [Member] | Contingent Payment Rights [Member]
Debt Instrument, Fair Value Disclosure	$ 4,100,000

Note 10 - Contingent Payment _4

Note 10 - Contingent Payment Obligations - Reconciliation Of Secured Contingent Obligation At Fair Value (Details) - Contingent Payment Obligation [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Proceeds from Issuance of Long-Term Debt	$ 5,000	$ 0
Repayments of Long-Term Debt	(13,925)	0
Secured Debt [Member]
Secured contingent payment obligation, beginning of year	40,708	37,372
Proceeds from Issuance of Long-Term Debt	5,000	0
Repayments of Long-Term Debt	(13,925)	0
Change in fair value	(2,381)	3,336
Secured contingent payment obligation, end of year	$ 29,402	$ 40,708

Note 10 - Contingent Payment _5

Note 10 - Contingent Payment Obligations - Reconciliation Of Unsecured Contingent Obligation At Fair Value (Details) - Contingent Payment Obligation [Member] - Unsecured Debt [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Unsecured contingent payment obligations, beginning of year	$ 5,089	$ 5,691
Change in fair value	2,529	(602)
Unsecured contingent payment obligations, end of year	$ 7,618	$ 5,089

Note 11 - Fair Value Measurem_3

Note 11 - Fair Value Measurements (Details Textual)	Dec. 31, 2023
Measurement Input, Discount Rate [Member] | Secured Debt [Member]
Debt Instrument, Measurement Input	0.1812
Measurement Input, Discount Rate [Member] | Unsecured Debt [Member]
Debt Instrument, Measurement Input	0.1851
Measurement Input, Risk Free Interest Rate [Member] | Secured Debt [Member]
Debt Instrument, Measurement Input	0.0412
Measurement Input, Risk Free Interest Rate [Member] | Unsecured Debt [Member]
Debt Instrument, Measurement Input	0.0451
Measurement Input, Entity Credit Risk [Member] | Secured Debt [Member]
Debt Instrument, Measurement Input	0.08
Measurement Input, Entity Credit Risk [Member] | Unsecured Debt [Member]
Debt Instrument, Measurement Input	0.08
Litigation Inherent Risk [Member] | Secured Debt [Member]
Debt Instrument, Measurement Input	0.06
Litigation Inherent Risk [Member] | Unsecured Debt [Member]
Debt Instrument, Measurement Input	0.06

Note 11 - Fair Value Measurem_4

Note 11 - Fair Value Measurements - Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Secured Contingent Payment Obligation [Member]
Liabilities	$ 29,402	$ 40,708
Secured Contingent Payment Obligation [Member] | Fair Value, Inputs, Level 1 [Member]
Liabilities	0	0
Secured Contingent Payment Obligation [Member] | Fair Value, Inputs, Level 2 [Member]
Liabilities	0	0
Secured Contingent Payment Obligation [Member] | Fair Value, Inputs, Level 3 [Member]
Liabilities	29,402	40,708
Unsecured Contingent Payment Obligation [Member]
Liabilities	7,618	5,089
Unsecured Contingent Payment Obligation [Member] | Fair Value, Inputs, Level 1 [Member]
Liabilities	0	0
Unsecured Contingent Payment Obligation [Member] | Fair Value, Inputs, Level 2 [Member]
Liabilities	0	0
Unsecured Contingent Payment Obligation [Member] | Fair Value, Inputs, Level 3 [Member]
Liabilities	$ 7,618	$ 5,089

Note 11 - Fair Value Measurem_5

Note 11 - Fair Value Measurements - Quantitative Information (Details) - Fair Value, Inputs, Level 3 [Member]	Dec. 31, 2023 USD ($) yr
Estimated Undiscounted Cash Outflows [Member] | Secured Debt [Member] | Minimum [Member]
Measurement input | $	0
Estimated Undiscounted Cash Outflows [Member] | Secured Debt [Member] | Weighted Average [Member]
Measurement input | $	43,100
Estimated Undiscounted Cash Outflows [Member] | Secured Debt [Member] | Maximum [Member]
Measurement input | $	79,600
Estimated Undiscounted Cash Outflows [Member] | Unsecured Debt [Member] | Minimum [Member]
Measurement input | $	0
Estimated Undiscounted Cash Outflows [Member] | Unsecured Debt [Member] | Weighted Average [Member]
Measurement input | $	9,700
Estimated Undiscounted Cash Outflows [Member] | Unsecured Debt [Member] | Maximum [Member]
Measurement input | $	10,800
Measurement Input, Expected Term [Member] | Secured Debt [Member] | Minimum [Member]
Measurement input | yr	0.5
Measurement Input, Expected Term [Member] | Secured Debt [Member] | Weighted Average [Member]
Measurement input | yr	2.3
Measurement Input, Expected Term [Member] | Secured Debt [Member] | Maximum [Member]
Measurement input | yr	3.5
Measurement Input, Expected Term [Member] | Unsecured Debt [Member] | Minimum [Member]
Measurement input | yr	0.5
Measurement Input, Expected Term [Member] | Unsecured Debt [Member] | Weighted Average [Member]
Measurement input | yr	1.4
Measurement Input, Expected Term [Member] | Unsecured Debt [Member] | Maximum [Member]
Measurement input | yr	3.5
Estimated Probabilities [Member] | Secured Debt [Member] | Minimum [Member]
Measurement input	0.05
Estimated Probabilities [Member] | Secured Debt [Member] | Weighted Average [Member]
Measurement input	0.20
Estimated Probabilities [Member] | Secured Debt [Member] | Maximum [Member]
Measurement input	0.35
Estimated Probabilities [Member] | Unsecured Debt [Member] | Minimum [Member]
Measurement input	0.05
Estimated Probabilities [Member] | Unsecured Debt [Member] | Weighted Average [Member]
Measurement input	0.23
Estimated Probabilities [Member] | Unsecured Debt [Member] | Maximum [Member]
Measurement input	0.35

Note 12 - Income Taxes and Ta_3

Note 12 - Income Taxes and Tax Status (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Current Income Tax Expense (Benefit)	$ 0	$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%
Operating Loss Carryforwards	$ 279,800
Operating Loss Carryforwards, Subject To Expiration	239,100
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	$ 4,600

Note 12 - Income Taxes and Ta_4

Note 12 - Income Taxes and Tax Status - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Tax expense (benefit) at statutory rate	$ 1,998	$ (2,061)
State tax expense (benefit)	409	(422)
(Decrease) increase in valuation allowance	(2,512)	2,416
Other	$ 105	$ 67

Note 12 - Income Taxes and Ta_5

Note 12 - Income Taxes and Tax Status - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Net operating loss carry-forward	$ 70,159	$ 75,470
Research and development credit carry-forward	4,565	5,356
Stock compensation	1,350	1,127
Patents and other	568	1,482
Contingent payment obligations	7,071	7,033
Fixed assets, tax liability	(1)	(2)
Charitable contributions	2	0
Lease liabilities	0	1
Deferred Tax Assets, Gross	83,714	90,467
Less valuation allowance	(83,714)	(90,467)
Net deferred tax asset	$ 0	$ 0

Note 12 - Income Taxes and Ta_6

Note 12 - Income Taxes and Tax Status - Schedule of Unrecognized Tax Beneifts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Unrecognized tax benefits – beginning of year	$ 638	$ 653
Reduction as a result of lapse of statute of limitations	0	(15)
Unrecognized tax benefits – end of year	$ 638	$ 638

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Details Textual) $ in Billions

1 Months Ended

12 Months Ended

24 Months Ended

35 Months Ended

Nov. 30, 2023

Apr. 30, 2020 USD ($)

Jul. 31, 2019

Mar. 31, 2018

Jul. 31, 2017

Mar. 31, 2017

Dec. 31, 2015

Dec. 31, 2023

Dec. 31, 2021

Dec. 31, 2023

Dec. 31, 2021

Dec. 31, 2022

Parkervision V. Qualcomm Middle District Of Florida [Member]

Gain Contingency, Patents Found Infringed upon, Number

3

Gain Contingency, Patents Allegedly Infringed upon, Number

6

Loss Contingency, Patents Split Decision, Number

2

Loss Contingency, Patents Allegedly Infringed, Seeking Invalidation, Number

4

Claim Construction, Number

7

Gain Contingency Damages Sought

$ 1.3

Parkervision V. Qualcomm Middle District Of Florida [Member] | Maximum [Member]

Claim Construction, Number

10

Parkervision V. Apple and Qualcomm Middle District of Florida [Member]

Gain Contingency, Patents Allegedly Infringed upon, Number

4

4

Claim Construction, Number

2

Loss Contingency, Patents Number, Motion To Dismiss

3

Parkervision V. Apple and Qualcomm Middle District of Florida [Member] | Maximum [Member]

Claim Construction, Number

6

Parkervision V. LG Electronics [Member]

Gain Contingency, Patents Allegedly Infringed upon, Number

4

Parkervision V. Intel Western District Of Texas [Member]

Gain Contingency, Patents Allegedly Infringed upon, Number

10

Parkervision V. TCL Western District Of Texas [Member]

Gain Contingency, Patents Allegedly Infringed upon, Number

12

Parkervision V. LGE Western District of Texas [Member]

Gain Contingency, Patents Allegedly Infringed upon, Number

10

Parkervision V. Realtek Western District of Texas [Member]

Gain Contingency, Patents Allegedly Infringed upon, Number

7

Parkervision V. Mediatek Western District Of Texas [Member]

Gain Contingency, Patents Allegedly Infringed upon, Number

10

Additional Number Of Patent Subject To Inter Parter Review

1

Parkervision V. Texas Instruments Western District of Texas [Member]

Gain Contingency, Patents Allegedly Infringed upon, Number

3

Parkervision V. NXP Semiconductors Western District of Texas [Member]

Gain Contingency, Patents Allegedly Infringed upon, Number

3

Note 14 - Stock Authorization_3

Note 14 - Stock Authorization and Issuance (Details Textual) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

2 Months Ended

3 Months Ended

12 Months Ended

Dec. 18, 2023

Nov. 22, 2022

Apr. 30, 2023

Jan. 31, 2023

Oct. 31, 2022

Jun. 30, 2022

Dec. 31, 2022

Mar. 31, 2023

Dec. 31, 2023

Sep. 16, 2022

Dec. 31, 2021

Nov. 17, 2005

Preferred Stock, Shares Authorized (in shares)

15,000,000

Preferred Stock, Shares Outstanding, Ending Balance (in shares)

0

Common Stock, Shares Authorized (in shares)

175,000,000

175,000,000

175,000,000

150,000,000

Stock Issued During Period, Value, Issued for Services

$ 127

Class of Warrant or Right, Outstanding (in shares)

10,300,000

10,300,000

Fair Value Adjustment of Warrants

$ 300

Class of Warrant or Right, Weighted Average Remaining Life (Year)

1 year 6 months

Weighted Average [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)

$ 0.75

Estimate of Fair Value Measurement [Member] | Additional Paid-in Capital [Member]

Warrants and Rights Outstanding

$ 3,200

$ 3,500

Warrants With Extended Expiration Dates [Member]

Class of Warrant or Right, Outstanding (in shares)

200,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)

$ 1

Fair Value Adjustment of Warrants

$ 20

Third Party Providing Consulting Services [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)

200,000

Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)

$ 0.21

Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Value

$ 30

Brickell [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)

$ 0.16

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

3,000,000

Lewis Titterton [Member]

Stock Issued During Period, Shares, New Issues (in shares)

250,000

Stock Issued During Period, Value, New Issues

$ 30

Intro Act [Member]

Stock Issued During Period, Value, New Issues

$ 20

Stock Issued During Period, Shares, Issued for Services (in shares)

150,000

75,000

Stock Issued During Period, Value, Issued for Services

$ 30

Sanford Litvack [Member]

Stock Issued During Period, Shares, New Issues (in shares)

62,500

Shares Issued, Price Per Share (in dollars per share)

$ 0.16

Private Placement With Contingent Purchase Rights [Member]

Stock Issued During Period, Shares, New Issues (in shares)

843,750

Shares Issued, Price Per Share (in dollars per share)

$ 0.16

Stock Issued During Period, Value, New Issues

$ 140

Private Placement With Contingent Purchase Rights [Member] | Sanford Litvack [Member]

Stock Issued During Period, Shares, New Issues (in shares)

62,500

Securities Purchase Agreements [Member]

Stock Issued During Period, Shares, New Issues (in shares)

2,000,000

Shares Issued, Price Per Share (in dollars per share)

$ 0.2

Stock Issued During Period, Value, New Issues

$ 400

Shareholder Approved Equity Compensation Plans [Member]

Common Stock, Capital Shares Reserved for Future Issuance (in shares)

1,100,000

Convertible Debt [Member]

Common Stock, Capital Shares Reserved for Future Issuance (in shares)

36,400,000

Conversion and Payment of Interest-in-kind on Convertible Debt [Member]

Common Stock, Capital Shares Reserved for Future Issuance (in shares)

1,400,000

Warrants and Options [member]

Common Stock, Capital Shares Reserved for Future Issuance (in shares)

36,400,000

Restricted Stock [Member] | Long Term Incentive Plan 2019 [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)

170,000

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested

$ 50

Series E Preferred Stock [Member]

Preferred Stock, Shares Authorized (in shares)

100,000

Note 14 - Stock Authorization_4

Note 14 - Stock Authorization and Issuance - Summary of Equity Offerings (Details) - Private Placement [Member] - $ / shares shares in Thousands		1 Months Ended
		Jan. 31, 2023	Dec. 31, 2022	Nov. 30, 2022
Stock Issued During Period, Shares, New Issues (in shares)		844	1,000	1,000
Shares Issued, Price Per Share (in dollars per share)		$ 0.16	$ 0.2	$ 0.2
Number of warrants issued (in shares)	[1]	120	200	200
[1]After deduction of applicable offering costs.

Note 15 - Share-based Compens_3

Note 15 - Share-based Compensation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Expense	$ 500,000	$ 3,100,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 150,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 4 months 24 days
Restricted Stock Units (RSUs) [Member] | Non Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	1 year
Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	1 year
Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
Restricted Stock Awards and Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 100,000	$ 30,000
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	25,834,000	24,180,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 0.24	$ 0.17
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value	$ 400,000	$ 3,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 0.004	$ 0.083
Long Term Incentive Plan 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	30,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee (in shares)	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee, Value	$ 175,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	24,730,086
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	1,136,467
Long Term Incentive Equity Plan 2011 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)		3,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)		1,103,969
The 2008 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)		50,000

Note 15 - Share-Based Compens_4

Note 15 - Share-Based Compensation - Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Awards and Restricted Stock Units (RSUs) [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Non-vested, shares (in shares)	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	370
Granted, grant date fair value (in dollars per share) | $ / shares	$ 0.3
Vested, shares (in shares)	(370)
Vested, grant date fair value (in dollars per share) | $ / shares	$ 0.3
Forfeited, shares (in shares)	0
Forfeited, grant date fair value (in dollars per share) | $ / shares	$ 0
Non-vested, shares (in shares)	0
Non-vested, grant date fair value (in dollars per share) | $ / shares	$ 0

Note 15 - Share-Based Compens_5

Note 15 - Share-Based Compensation - Share-Based Compensation, Stock Options Activity (Details) - Share-Based Payment Arrangement, Option [Member] $ / shares in Units, shares in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares
Outstanding, shares (in shares) | shares	24,180
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 0.41
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares	2,000
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 0.26
Exercised, shares (in shares) | shares	(21)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 0.17
Forfeited/Expired, shares (in shares) | shares	(325)
Forfeited/Expired, weighted average exercise price (in dollars per share) | $ / shares	$ 0.86
Outstanding, shares (in shares) | shares	25,834
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 0.4
Outstanding, weighted average remaining contractual term (Year)	2 years 6 months
Outstanding, aggregate intrinsic value | $	$ 0
Vested, shares (in shares) | shares	24,659
Vested, weighted average exercise price (in dollars per share) | $ / shares	$ 0.4
Vested, weighted average remaining contractual term (Year)	2 years 4 months 24 days
Vested, aggregate intrinsic value | $	$ 0

Note 15 - Share-Based Compens_6

Note 15 - Share-Based Compensation - Schedule of Share-Based Payment Award Stock Options, Valuation Assumptions (Details) - Share-Based Payment Arrangement, Option [Member]		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Expected option term (in years) 1 (Year)	[1]	5 years	5 years
Expected annual dividend yield		0%	0%
Minimum [Member]
Expected volatility factor 2	[2]	150.90%	143.90%
Risk-free interest rate 3	[3]	3.60%	3.05%
Maximum [Member]
Expected volatility factor 2	[2]	155.90%	155.90%
Risk-free interest rate 3	[3]	4.45%	4.09%
[1]The expected term was generally determined based on historical activity for grants with similar terms and for similar groups of employees and represents the period of time that options are expected to be outstanding. For employee options, groups of employees with similar historical exercise behavior are considered separately for valuation purposes.[2]The stock volatility for each grant is measured using the weighted average of historical daily price changes of our common stock over the most recent period equal to the expected option life of the grant.[3]The risk-free interest rate for periods equal to the expected term of the share option is based on the U.S. Treasury yield curve in effect at the measurement date.

Note 15 - Share-based Compens_7

Note 15 - Share-based Compensation - Schedule of Share Based Compensation, Shares Authorized Under Stock Option Plans By Exercise Price Range (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Options outstanding, number (in shares) | shares	25,834
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.4
Options outstanding, weighted average contractual life (Year)	2 years 6 months
Options vested, number (in shares) | shares	24,659
Options vested, weighted average exercise price (in dollars per share)	$ 0.4
Options vested, weighted average contractual life (Year)	2 years 4 months 24 days
Exercise Price Range One [Member]
Exercise price, lower limit (in dollars per share)
Exercise price, upper limit (in dollars per share)
Options outstanding, number (in shares) | shares	11,458
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.19
Options outstanding, weighted average contractual life (Year)	3 years 1 month 6 days
Options vested, number (in shares) | shares	10,283
Options vested, weighted average exercise price (in dollars per share)	$ 0.18
Options vested, weighted average contractual life (Year)	3 years
Exercise Price Range Two [Member]
Exercise price, lower limit (in dollars per share)
Exercise price, upper limit (in dollars per share)
Options outstanding, number (in shares) | shares	550
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.33
Options outstanding, weighted average contractual life (Year)	3 years 1 month 6 days
Options vested, number (in shares) | shares	550
Options vested, weighted average exercise price (in dollars per share)	$ 0.33
Options vested, weighted average contractual life (Year)	3 years 1 month 6 days
Exercise Price Range Three [Member]
Exercise price, lower limit (in dollars per share)
Exercise price, upper limit (in dollars per share)
Options outstanding, number (in shares) | shares	13,553
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.54
Options outstanding, weighted average contractual life (Year)	2 years
Options vested, number (in shares) | shares	13,553
Options vested, weighted average exercise price (in dollars per share)	$ 0.54
Options vested, weighted average contractual life (Year)	2 years
Exercise Price Range Four [Member]
Exercise price, lower limit (in dollars per share)
Exercise price, upper limit (in dollars per share)
Options outstanding, number (in shares) | shares	273
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.98
Options outstanding, weighted average contractual life (Year)	7 months 6 days
Options vested, number (in shares) | shares	273
Options vested, weighted average exercise price (in dollars per share)	$ 1.98
Options vested, weighted average contractual life (Year)	7 months 6 days

Note 16 - Related Party Trans_2

Note 16 - Related Party Transactions (Details Textual) $ / shares in Units, $ in Thousands, Pure in Millions	1 Months Ended			12 Months Ended		24 Months Ended
	Apr. 30, 2023 USD ($) shares	Jan. 31, 2023 $ / shares shares	Aug. 31, 2022 USD ($) $ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2023 USD ($) $ / shares	Sep. 15, 2023 USD ($) $ / shares	May 31, 2022 USD ($) $ / shares
Convertible Debt				$ 4,938	$ 4,538	$ 4,938
Lewis Titterton [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	250,000
Stock Issued During Period, Value, New Issues	$ 30
Sterne Kessler Goldstein Fox Pllc [Member] | Patent-Related Legal Services [Member]
Related Party Transaction, Amounts of Transaction				50		10
Sterne Kessler Goldstein Fox Pllc [Member] | Promissory Notes [Member] | Unsecured Debt [Member]
Repayments of Long-Term Debt				200	$ 100
Notes Payable				500		500
Lewis Titterton [Member] | Promissory Notes [Member]
Convertible Debt				$ 330		330
Debt Instrument, Convertible, Number of Equity Instruments				2.7
Paul Rosenbaum [Member] | Promissory Notes [Member]
Convertible Debt				$ 200		$ 200		$ 100
Debt Instrument, Convertible, Number of Equity Instruments				1.2
Debt Instrument, Face Amount							$ 100		$ 100
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares							$ 0.25	$ 0.25	$ 0.13
Sanford Litvack [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares		62,500
Shares Issued, Price Per Share (in dollars per share) | $ / shares		$ 0.16
Sanford Litvack [Member] | Promissory Notes [Member]
Debt Instrument, Convertible, Number of Equity Instruments			0.2
Debt Instrument, Face Amount			$ 30
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares			$ 0.13